Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 12.5% in the morning session after Peter Marks, the ...

Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

Shares of Moderna (NASDAQ: MRNA) are falling on Monday. The steep decline comes as the S&P 500 and Nasdaq Composite lost 0.4% ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Looking at options history for Moderna (NASDAQ:MRNA) we detected 38 trades. If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish ...

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger drugmakers, ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

BMO Capital Markets analyst Evan David Seigerman called the resignation a "significant negative" for biotech and biopharma companies, especially vaccine manufacturers like Moderna. He explained ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on ...